Actively Recruiting

Age: 18Years - 70Years
All Genders
ID07302100

Nutritional Status Assessment in Adult Patients Followed for Gastroenteropancreatic Neuroendocrine Tumors at Strasbourg University Hospital

Led by University Hospital, Strasbourg, France · Updated on 2025-12-24

100

Participants Needed

1

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

Neuroendocrine tumors are a diverse group of tumors, with gastrointestinal (gastroenteropancreatic) NETs being the most common. These tumors are usually well-differentiated and slow-growing, often associated with a median overall survival of up to 9 years. Managing these tumors involves controlling symptoms and tumor growth, using treatments like surgery, systemic therapies, and targeted radiotherapy. Nutritional status may influence the prognosis and quality of life in patients with these tumors, and this study explores that potential link. This observational study follows adult patients aged 18 to 70 years who are monitored for digestive neuroendocrine tumors diagnosed between 2000 and 2024. The research focuses on assessing patients' nutritional status and its association with their prognosis. It tracks the proportion of patients experiencing malnutrition over a period of up to 12 months. Participants will be observed during routine care without additional interventions, with data collected on their nutritional health and tumor status. Researchers will measure malnutrition rates and analyze how nutritional factors relate to patient outcomes. The study will continue until February 2026, aiming to provide insights that could improve the support and treatment strategies for patients with gastroenteropancreatic NETs.

CONDITIONS

Brief Title

Nutritional Status Assessment in Adult Patients Followed for Gastroenteropancreatic Neuroendocrine Tumors at Strasbourg University Hospital

Who Can Participate

Age: 18Years - 70Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Adults aged 18 to 70 years
  • Patients being monitored for a digestive neuroendocrine tumor (gastric, pancreatic, intestinal)
  • Diagnosis made between January 1, 2000, and November 30, 2024
Not Eligible

You will not qualify if you...

  • Tumor reclassified as non-neuroendocrine by histopathology

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Long-term Monitoring

Duration - Up to 12 months

Participants with gastroenteropancreatic neuroendocrine tumors are observed to assess their nutritional status over time.

Visits as determined by routine clinical follow-up

Trial Site Locations

Total: 1 location

1

Service d'Endocrinologie, Diabétologie, Nutrition - CHU de Strasbourg - France

Strasbourg, France, 67091

Actively Recruiting

Loading map...

Research Team

P

Philippe BALTZINGER, MD

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

0

Similar Trials

68Ga-DOTATOC PET for the Evaluation of Gastroenteropancreati...

Gastroenteropancreatic Neuroendocrine Tumor

Actively Recruiting

1 location

Continuing Somatostatin Analogues Upon Progression in Neuroe...

Gastroenteropancreatic Neuroendocrine Tumor

Actively Recruiting

19 locations

IMMUNORARE5: National Phase II Trials of Domvanalimab and Zi...

Peritoneal Mesothelioma

Actively Recruiting

15 locations

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here